Zobrazeno 1 - 10
of 1 110
pro vyhledávání: '"disease modifying drugs"'
Autor:
Brian M. Ou Yong, Wireko Andrew Awuah, Muhammad Hamza Shah, Vivek Sanker, Jonathan Kong Sing Huk, Sujashree Yadala Venkata, Diti H. Patel, Joecelyn Kirani Tan, Noor Ayman Khan, Ajitha Kulasekaran, Manali Sarkar, Toufik Abdul-Rahman, Oday Atallah
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-13 (2024)
Abstract Multiple Sclerosis (MS) is a complex autoimmune disorder that significantly impacts the central nervous system, leading to a range of complications. While intracranial haemorrhage (ICH) is a rare but highly morbid complication, more common C
Externí odkaz:
https://doaj.org/article/50ccca69513e4cc28fea3138d2b13608
Autor:
Nasrin Abulhasanbeigi Gallehzan, Majid Khosravi, Khosro Jamebozorgi, Nazanin Mir, Habib Jalilian, Samira Soleimanpour, Saeed Hoseini, Aziz Rezapour, Abbas Eshraghi
Publikováno v:
Health Economics Review, Vol 14, Iss 1, Pp 1-37 (2024)
Abstract Background Multiple sclerosis (MS) is a chronic, autoimmune, and inflammatory disease. The economic burden of MS is substantial, and the high cost of Disease-modifying drugs (DMDs) prices are the main drivers of healthcare expenditures. We c
Externí odkaz:
https://doaj.org/article/96415d0a4a3b46258b80319c370323e8
Autor:
Jonas Graf, Huah Shin Ng, Feng Zhu, Yinshan Zhao, José MA. Wijnands, Charity Evans, John D. Fisk, Ruth Ann Marrie, Helen Tremlett
Publikováno v:
The Lancet Regional Health. Americas, Vol 29, Iss , Pp 100667- (2024)
Summary: Background: Much remains unknown surrounding the disease-modifying drugs (DMDs) used to treat multiple sclerosis and infection-related healthcare use in the ‘real-world’ setting. We examined if DMD exposure was associated with altered in
Externí odkaz:
https://doaj.org/article/08f40bd1eabf4c93befd0f581c46326a
Autor:
Lisa Sequeira, Sofia Benfeito, Carlos Fernandes, Inês Lima, Joana Peixoto, Catarina Alves, Cláudia Sofia Machado, Alexandra Gaspar, Fernanda Borges, Daniel Chavarria
Publikováno v:
Pharmaceutics, Vol 16, Iss 6, p 708 (2024)
Neurodegenerative diseases (NDs) are a set of progressive, chronic, and incurable diseases characterized by the gradual loss of neurons, culminating in the decline of cognitive and/or motor functions. Alzheimer’s disease (AD) and Parkinson’s dise
Externí odkaz:
https://doaj.org/article/4f4992fa6ba147229fcec8fab99b946a
Autor:
Karmela Filipović, Jelena Zvekić-Svorcan, Cila Demesi Drljan, Milan Cvetković, Dragan Marinković, Marko Erceg
Publikováno v:
Acta Clinica Croatica, Vol 61., Iss 3, Pp 436-448 (2022)
Osteoarthritis (OA) can be treated using either a pharmacological or non-pharmacological approach, or a combination of both. The purpose of the present study was to investigate the efficacy of crystalline glucosamine sulfate (CGS) in patients with
Externí odkaz:
https://doaj.org/article/579298a54c2d4190bc226a3d1d6d7874
Autor:
Vera Damuzzo, Laura Agnoletto, Roberta Rampazzo, Francesca Cammalleri, Luca Cancanelli, Marco Chiumente, Stefano Costantino, Silvia Michielan, Federica Milani, Alessia Sartori, Melania Rivano, Daniele Mengato
Publikováno v:
Neurology International, Vol 13, Iss 4, Pp 682-694 (2021)
Health-related quality of life is frequently included in patient-reported outcomes aimed at evaluating the effectiveness of disease-modifying drugs for multiple sclerosis, but recent data about Italian patients are missing. A multicenter observationa
Externí odkaz:
https://doaj.org/article/9a7b6c9a184a43e7a57b929803249ede
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Recent advances in managing Sickle Cell Disease (SCD) significantly improved patient survival and quality of life. Disease-modifying drug therapies such as hydroxyurea, L-glutamine, voxelotor, and crizanlizumab reduce pain crises and severe complicat
Externí odkaz:
https://doaj.org/article/07378119d7ab44d484e81a3315d94a62
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 15, Pp 2921-2945 (2021)
Win Min Oo,1,2 Christopher Little,3 Vicky Duong,1 David J Hunter1 1Rheumatology Department, Royal North Shore Hospital, and Institute of Bone and Joint Research, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Aus
Externí odkaz:
https://doaj.org/article/8c0d029e7da04baab6c9afc728aec558
Autor:
I. E. H. Kremer, P. J. Jongen, S. M. A. A. Evers, E. L. J. Hoogervorst, W. I. M. Verhagen, M. Hiligsmann
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 21, Iss 1, Pp 1-18 (2021)
Abstract Background Since decision making about treatment with disease-modifying drugs (DMDs) for multiple sclerosis (MS) is preference sensitive, shared decision making between patient and healthcare professional should take place. Patient decision
Externí odkaz:
https://doaj.org/article/f25b61f2f2754a708c0c07e07cb53779
Autor:
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A. Leiter, Antonio Ceriello, Ralph A. DeFronzo, Itamar Raz
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)
Abstract During the last decade we experienced a surge in the number of glucose lowering agents that can be used to treat patients with type 2 diabetes. Especially important are the discoveries that sodium glucose co-transporter type 2 inhibitors (SG
Externí odkaz:
https://doaj.org/article/79f3680a60234f788c2aad9443e2342f